Literature DB >> 3134120

Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report.

M J Duffy1, P O'Grady, D Devaney, L O'Siorain, J J Fennelly, H J Lijnen.   

Abstract

Plasminogen activator is a serine protease which exists in two forms, known as tissue-type plasminogen activator and urokinase-type plasminogen activator. Here, we show that urokinase-type plasminogen activator activity in primary breast carcinomas correlates with both size of tumor and number of axillary nodes with metastases. Patients with primary carcinomas containing high levels of urokinase-type plasminogen activator activity had a significantly shorter disease-free interval than patients with low levels of activity. It is concluded that urokinase-plasminogen activator may be a new prognostic marker in breast cancer.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3134120     DOI: 10.1002/1097-0142(19880801)62:3<531::aid-cncr2820620315>3.0.co;2-b

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  59 in total

Review 1.  The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer.

Authors:  G Cox; W P Steward; K J O'Byrne
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

2.  Ca&sup2+;-Dependent Neutral Protease (Calpain) Activity in Breast Cancer Tissue and Estrogen Receptor Status.

Authors: 
Journal:  Breast Cancer       Date:  1996-03-29       Impact factor: 4.239

3.  The Oral Serine Protease Inhibitor WX-671 - First Experience in Patients with Advanced Head and Neck Carcinoma.

Authors:  Jens E Meyer; Carsten Brocks; Hendrik Graefe; Carola Mala; Natalie Thäns; Markus Bürgle; Annette Rempel; Nicole Rotter; Barbara Wollenberg; Stephan Lang
Journal:  Breast Care (Basel)       Date:  2008-10-16       Impact factor: 2.860

4.  Assessment of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in Breast Cancer Tissue: Historical Aspects and Future Prospects.

Authors:  Manfred Schmitt; Karin Mengele; Apostolos Gkazepis; Rudolf Napieralski; Viktor Magdolen; Ute Reuning; Nadia Harbeck
Journal:  Breast Care (Basel)       Date:  2008-10-15       Impact factor: 2.860

5.  Prospective Biomarker Trials Chemo N0 and NNBC-3 Europe Validate the Clinical Utility of Invasion Markers uPA and PAI-1 in Node-Negative Breast Cancer.

Authors:  Nadia Harbeck; Manfred Schmitt; Martina Vetter; Janna Krol; Daniela Paepke; Mathias Uhlig; Stefan Paepke; Fritz Jänicke; Anneke Geurts-Moespot; Gunter von Minckwitz; Fred Sweep; Christoph Thomssen
Journal:  Breast Care (Basel)       Date:  2008-10-16       Impact factor: 2.860

Review 6.  Utilizing prognostic and predictive factors in breast cancer.

Authors:  Deepa S Subramaniam; Claudine Isaacs
Journal:  Curr Treat Options Oncol       Date:  2005-03

7.  Spontaneous lung and lymph node metastasis in transgenic breast cancer is independent of the urokinase receptor uPAR.

Authors:  Kasper Almholt; Ole Didrik Lærum; Boye Schnack Nielsen; Ida Katrine Lund; Leif Røge Lund; John Rømer; Annika Jögi
Journal:  Clin Exp Metastasis       Date:  2015-06-04       Impact factor: 5.150

8.  6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.

Authors:  Benjamin J Buckley; Ashraf Aboelela; Elahe Minaei; Longguang X Jiang; Zhihong Xu; Umar Ali; Karen Fildes; Chen-Yi Cheung; Simon M Cook; Darren C Johnson; Daniel A Bachovchin; Gregory M Cook; Minoti Apte; Mingdong Huang; Marie Ranson; Michael J Kelso
Journal:  J Med Chem       Date:  2018-09-07       Impact factor: 7.446

9.  (4-aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase.

Authors:  S Sperl; U Jacob; N Arroyo de Prada; J Stürzebecher; O G Wilhelm; W Bode; V Magdolen; R Huber; L Moroder
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

10.  Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism.

Authors:  Kenneth A Botkjaer; Elena I Deryugina; Daniel M Dupont; Henrik Gårdsvoll; Erin M Bekes; Cathrine K Thuesen; Zhuo Chen; Zhou Chen; Michael Ploug; James P Quigley; Peter A Andreasen
Journal:  Mol Cancer Res       Date:  2012-10-04       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.